Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Group Therapy01:26

Group Therapy

451
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
451
What are Cells?01:07

What are Cells?

202.3K
Cells are the smallest and basic units of life, whether it is a single cell that forms the entire organism, e.g., in a bacterium or trillions of them, e.g., in humans. No matter what organism a cell is a part of, they share specific characteristics.
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...
202.3K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Behavior Therapy01:22

Behavior Therapy

729
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
729

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Blood immunology & cellular therapy·2026
Same author

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Blood·2026
Same author

Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Hematology/oncology and stem cell therapy·2026
Same author

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Blood·2026
Same author

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Feb 8, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.5K

CAR T cell therapy for B-cell lymphomas.

Julio C Chavez1, Frederick L Locke2

  • 1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA.

Best Practice & Research. Clinical Haematology
|June 19, 2018
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell therapy offers a new treatment option for patients with refractory B-cell non-Hodgkin

Keywords:
Aggressive lymphomasCARTDiffuse large B cell lymphomaImmunotherapyRefractory

More Related Videos

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

899
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Feb 8, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.5K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

899
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Hematology and Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • B-cell non-Hodgkin's lymphomas (NHLs), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), are heterogeneous malignancies.
  • Standard chemoimmunotherapy is effective but a subset of patients with high-risk features face refractory disease and limited curative options.
  • Adoptive immunotherapy with chimeric antigen receptor (CAR) T-cells represents a promising therapeutic advancement for these challenging cases.

Purpose of the Study:

  • To review the biological characteristics of poor-prognosis DLBCL and FL.
  • To elucidate the rationale for employing CAR T-cell therapy in malignant lymphomas.
  • To analyze the efficacy and safety profiles of CD19-directed CAR T-cell therapy across various clinical trial settings.

Main Methods:

  • Review of existing literature on the biology of high-risk DLBCL and FL.
  • Analysis of the scientific rationale supporting CAR T-cell therapy in lymphoma.
  • Synthesis of data from early single-center studies to global multicenter trials evaluating CD19-directed CAR T-cell constructs.

Main Results:

  • CAR T-cell therapy demonstrates significant efficacy in treating refractory DLBCL and FL.
  • The review encompasses data from early-phase investigations to large-scale clinical trials.
  • An assessment of the efficacy and toxicity profile of CD19-targeted CAR T-cells is presented.

Conclusions:

  • CAR T-cell therapy is a viable and effective treatment modality for patients with refractory B-cell lymphomas.
  • Understanding the biology of poor-risk lymphomas is crucial for optimizing CAR T-cell therapy strategies.
  • CD19-directed CAR T-cell therapy shows a promising efficacy and toxicity balance in clinical practice.